Verrica Pharmaceuticals Inc. Proceeds from Debt, Net of Issuance Costs
Verrica Pharmaceuticals Inc. (VRCA) reported Proceeds from Debt, Net of Issuance Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-03-11
- Verrica Pharmaceuticals Inc. proceeds from debt, net of issuance costs for the quarter ending 2024-12-31 was $0.00.
- Verrica Pharmaceuticals Inc. proceeds from debt, net of issuance costs for the quarter ending 2023-12-31 was $0.00.
- Verrica Pharmaceuticals Inc. proceeds from debt, net of issuance costs for the quarter ending 2022-12-31 was $0.00.
- Verrica Pharmaceuticals Inc. proceeds from debt, net of issuance costs for the quarter ending 2022-09-30 was $0.00.
- Verrica Pharmaceuticals Inc. proceeds from debt, net of issuance costs for fiscal 2025 was $0.00.
- Verrica Pharmaceuticals Inc. proceeds from debt, net of issuance costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Verrica Pharmaceuticals Inc. proceeds from debt, net of issuance costs for fiscal 2023 was $44.10M.
- Verrica Pharmaceuticals Inc. proceeds from debt, net of issuance costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-11 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 10-K · filed 2026-03-11 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-05 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $44.10M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $44.10M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $4.97M 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $4.97M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $4.97M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $4.97M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $34.46M 10-K · filed 2022-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |